VistaGen
Therapeutics employs the expertise of company co-founder and renowned Canadian
stem cell scientist Dr. Gordon Keller, as well as co-founder, president, and
chief scientific officer Dr. Ralph Snodgrass.
Human Clinical
Trials in a Test Tube™, the company’s human pluripotent stem cell (hPSC)
technology platform, was developed using a combination of proprietary and
exclusively licensed hPSC technologies, including those originating from two
decades of research by Drs. Keller and Snodgrass.
The platform’s
underlying technologies enable controlled differentiation of hPSCs into mature
human cells specific to VistaGen’s current and potential predictive toxicology,
drug metabolism, drug rescue, and regenerative cell therapy programs and
commercial programs.
Utilizing these
technologies, VistaGen is currently developing CardioSafe 3D™, a novel
biological assay system that uses mature human heart cells derived from hPSCs
to screen for heart toxicity in connection with the company’s drug rescue
activities; LiverSafe 3D™, for predicting liver toxicity and metabolism issues
in connection with the company’s drug rescue activities; and AV-101, a novel,
orally available prodrug candidate focused on the treatment of neuropathic
pain, depression, and potentially other neurological conditions.
VistaGen’s
overarching goal is to combine its hPSC technology with medicinal chemistry to
generate new, proprietary, chemical variants of small molecule drug candidates
that were shelved due to unexpected heart or liver safety concerns.
The company believes
its Human Clinical Trials in a Test Tube™ platform enables a more rapid and
precise safety profile of drug rescue variants, allowing the company to
generate a pipeline of drug rescue variants that it will license or sell to biotechnology
and pharmaceutical companies that can further develop the products and bring
them to market.
For more
information, visit www.vistagen.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment